BDI Pharma, Inc. Chosen as Authorized Distributor for Coagadex®
Specialty distributor to offer access to first and only FDA-approved treatment for hereditary factor X deficiency
COLUMBIA, S.C., Nov. 2, 2015 /PRNewswire/ -- BDI Pharma, Inc., the nation's fastest growing, independently owned specialty pharmaceutical distributor, today announced it has been selected by Bio Products Laboratory (BPL) as an Authorized Distributor of Record (ADR) for Coagadex (Coagulation Factor X, Human). On October 20, 2015, Coagadex was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults and children (aged 12 years and over) with hereditary factor X deficiency for on-demand treatment and control of bleeding episodes, and perioperative management of bleeding in patients with mild hereditary factor X deficiency.
Logo - http://photos.prnewswire.com/prnh/20151102/282844LOGO
Similar in character to hemophilia A and hemophilia B, hereditary factor X deficiency is one of the rarest bleeding disorders affecting approximately 300-600 patients in the U.S. Affected individuals often have inadequate amounts of circulating factor X, an important component of the coagulation system. Factor X deficient patients are at increased risk of bleeding and need to be managed through replacement therapy similarly to hemophilia patients.
"We are proud to have been selected as an ADR for this groundbreaking new hemophilia therapy," stated Richard Gaton, president and co-founder of BDI Pharma. "The addition of Coagadex to our orphan product portfolio further aligns our mission with the goals and needs of the rare disease community."
Coagadex is expected to be available in the U.S. in December 2015. Contact a BDI Pharma representative to obtain more information about the product or to inquire about ordering.
Please see the full prescribing information for Coagadex at www.coagadex.com.
About BDI Pharma, Inc.
BDI Pharma creates customized solutions to meet the distribution and support needs of manufacturers, healthcare providers, and patients throughout the life of each product within the specialty, niche pharmaceutical market. We aspire towards financial viability for all parties involved, employ a partnership oriented approach, and drive value for our customers. We are continuously refining the concept of niche distribution to provide solutions beyond the traditional wholesaler model and operate as an extension of our partners' sales force, create demand, and move market share with each transaction. Our approach of serving the manufacturers as well as healthcare providers and patients over the last two decades has proven successful regardless of varying market conditions. This is further supplemented through innovative supply solutions, extensive product knowledge, 24/7 emergency availability and urgent need delivery. The company's website www.bdipharma.com serves as a reference for educational material and online ordering along with comprehensive reimbursement services and product consignment offerings custom tailored to the needs of the entire healthcare community. BDI Pharma's product portfolio includes IVIG, branded and generic specialty pharmaceuticals, chemotherapy, vaccines, albumin, coagulation factors, high-titer or "hyper" immune globulins, and other niche, specialty products. BDI Pharma is recognized as an "ADR," or Authorized Distributor of Record, for all of the manufacturers it represents.
Contact: Brad Davis
800-948-9834
Email
SOURCE BDI Pharma, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article